Document Detail


Prospective multicenter study of HX575 (biosimilar epoetin-α) in patients with chronic kidney disease applying a target hemoglobin of 10 - 12 g/dl.
MedLine Citation:
PMID:  22732334     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
HX575 was approved in the European Union in August 2007 as the firstever biosimilar epoetin-α product. The present study extended the safety database on HX575 by monitoring adverse events (AEs) in clinical practice. Hemoglobin (Hb) levels and HX575 doses were recorded for the assessment of efficacy. This open, 6-month single-arm study was conducted in 10 European countries with a target enrollment of 1,500 patients with anemia due to chronic kidney disease (CKD). HX575 was intravenously (i.v.) administered aiming at an Hb target of 10 - 12 g/dl. Most patients (92.3%) had already received erythropoiesis stimulating agents (ESAs) treatment before enrolment into this study; the recorded treatments mainly comprised i.v. or subcutaneous (s.c.) administration of epoetin-α, epoetin-β or darbepoetin. The study period covered 770 patient years. The observed AE profile was in line with expectations for this patient population. Thrombotic vascular events (TVEs) were reported in 11.9% of patients (0.2612 per patient year). Tumor incidence was 1.4% (0.0299 per patient year). No subject developed anti-epoetin antibodies. Mean Hb levels were effectively maintained between 11.2 and 11.3 g/dl following the conversion from a broad spectrum of pre-study ESA treatments with stable overall mean i.v. HX575 doses. The proportion of patients within the Hb target range increased from 57.5% at baseline to 66.8% at study end.
Authors:
Walter H Hörl; Francesco Locatelli; Marianne Haag-Weber; Marité Ode; Karsten Roth
Related Documents :
2451374 - A follow-up study of leg and foot ulcer patients.
1065284 - Serum gestrin in chinese patients with peptic ulcer.
6833534 - Moist wound healing under a vapor permeable membrane.
17134384 - Analysis of therapy-resistant venous leg ulcers. can triple-layer treatment initiate he...
8503794 - Interictal metabolic anatomy of mesial temporal lobe epilepsy.
10601404 - Urinary dysfunction and orthostatic hypotension in multiple system atrophy: which is th...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical nephrology     Volume:  78     ISSN:  0301-0430     ISO Abbreviation:  Clin. Nephrol.     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-06-26     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0364441     Medline TA:  Clin Nephrol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  24-32     Citation Subset:  IM    
Affiliation:
Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria, Department of Nephrology, Dialysis and Renal Transplant, Alessandro Manzoni Hospital, Lecco, Italy, KfH Kidney Center, St. Elisabeth Hospital, Straubing, Germany, Sandoz Biopharmaceuticals, Hexal AG, Holzkirchen, Germany and the Epo-PASS study group.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Acute and long-term effects of corticosteroid therapy on bone metabolism in patients with kidney dis...
Next Document:  Serum prolactin and macroprolactin levels in diabetic nephropathy.